DC vaccine for treating chronic hepatitis B

A vaccine and specific technology, applied in the direction of antibody medical components, pharmaceutical formulations, antiviral agents, etc., can solve problems such as functional defects, low ability of T lymphocyte proliferation, and reduced number of proliferation

Inactive Publication Date: 2007-06-20
解放军三〇二医院生物治疗研究中心
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The research in our laboratory also found that the proliferation of DC in the peripheral blood of patients with chronic HBV infection was significantly lower than that of normal people; the levels of CD1a, CD86, CD80 and HLA-DR expressed on the surface of DC in patients with chronic hepatitis B were significantly lower than normal; In the mixed lymphocyte reaction (mixed lymphocyte reaction, MLR), the ability of DC from hepatitis B patients to stimulate T lymphocyte proliferation is also lower than that of healthy people; the level of IL-12 produced in MLR supernatant and pure DC culture supernatant is reduced However, the level of NO increases, and NO is considered to damage healthy tissues by inhibiting the action of various enzymes. It can be seen that patients with chronic hepatitis B not only have immature DC phenotypes but also have functional defects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DC vaccine for treating chronic hepatitis B
  • DC vaccine for treating chronic hepatitis B
  • DC vaccine for treating chronic hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The present invention is further illustrated by the following examples, but not as a limitation of the present invention. Embodiment 1, preparation

[0056] 1. The source of HBsAg and HBcAg: HBsAg comes from the semi-finished product of recombinant (yeast) hepatitis B vaccine without immune adjuvant. HBcAg is derived from the plasmid PMM2066 carrying the full gene sequence of HBcAg constructed in our laboratory, which is isolated and purified after expression in Escherichia coli.

[0057] 2. Isolation of PBMCs on day 0: Take 100ml of peripheral anticoagulant blood, separate PBMCs with lymphocyte separation medium, dilute the separated PBMCs to 20ml with pre-cooled PBS, divide them into two sterilized 10ml centrifuge tubes, and centrifuge Twice for 10 minutes to remove cell debris and platelets, and discard the supernatant. The PBMC depleted of cell debris and platelets were further diluted with PBS. Add the lymphocyte separation medium that has been returned to room ...

Embodiment 2

[0071] Embodiment 2: the preparation of injection

[0072] The vaccine obtained in step 7 or 9 of Example 1 was dissolved in water for injection according to the following formula, and prepared into injection according to conventional techniques.

[0073] Vaccine 1×10 7

[0074] Potassium chloride 0.04mg

[0075] Potassium dihydrogen phosphate 0.04mg

[0076] Sodium chloride 1.6mg

[0077] Disodium hydrogen phosphate .7H 2 O 0.432mg

[0078] The injection solution was prepared with distilled water to a final volume of 200 μl.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

A therapeutic DC vaccine for preventing and treating chronic hepatitis B is a hepatitis B specific DC vaccine carried by both HBsAg and HBcAg. The dendritic cells coming from mononuclear cells are carried by both recombinant HBV surface antigen and recombinant HBV core antigen.

Description

Technical field: [0001] The present invention relates to a mononuclear cell derived mononuclear cell loaded with recombinant hepatitis B virus (hepatitis B virus, HBV) surface antigen (hepatitis B virus surface antigen, HBsAg) and recombinant hepatitis B virus core antigen (HBcAg) simultaneously Dendritic cells (monocyte derived-DC, moDC) are HBV-specific DC vaccines made by enabling the dendritic cells to be loaded with antigens and mature. Background technique: [0002] Hepatitis B virus is caused by HBV, a group of infectious diseases mainly caused by liver inflammation and necrosis, and is one of the diseases that seriously endanger human health. According to the World Health Organization, there are more than 2 billion HBV-infected people worldwide, of which 400 million are chronically infected. 10-20% of patients with chronic infection may develop liver cirrhosis, and 1-5% of liver cirrhosis may evolve into hepatocellular carcinoma (HCC). Therefore, the occurrence of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/29A61K9/08A61P31/12
Inventor 王福生施明金磊陈威巍
Owner 解放军三〇二医院生物治疗研究中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap